From Our Partners
Wednesday, July 6, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

First Hookwarm Vaccine Passes Safety Trial

by Global Biodefense Staff
October 8, 2014
Hookworm Strongyloides

Hookworm Strongyloides. Credit; Dr. Mae Melvin/CDC

The first vaccine against hookworm has been shown to be safe in clinical trials in Brazil, according to researchers from the Sabin Vaccine Institute Product Development Partnership who led the trial.

The vaccine—which was developed by the HOOKVAC consortium—was well tolerated by 102 healthy volunteers, and blood tests indicated they developed an immune response.

Hookworms are parasites that infect more than 600 million people globally by attaching themselves to a host’s intestines and feeding off his or her blood. Hookworm infections can leads to conditions such as iron deficiency and capillary damage, as well as impede a child’s mental development and growth.

Researchers hope that a vaccine will serve as an alternative way to handle repeat hookworm infections. Although drugs do exist to kill the hookworms, individuals are often re-infected through contaminated water. An effective vaccine could both treat existing infections and provide lasting immunity against reinfection.

“A vaccine able to induce long-lasting immunity, which could be incorporated into existing vaccination programmes in countries like Brazil, would provide a sustainable solution to the problem of hookworm,” said David Diemert, director of clinical trials at Sabin.

Diemert says it could be several years until the vaccine has undergone the necessary tests to be approved for use, but hopes the vaccine will be available and licensed by 2020.

To read more about the hookworm vaccine trial, click here.

From Our Partners
Tags: Vaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Biodefense Headlines – 5 July 2022

Biodefense Headlines – 5 July 2022

July 5, 2022
Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC